After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...
Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...
Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood ...
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases ...
Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...
Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...
New data from a phase 3 trial measuring Roche’s Vabysmo versus Regeneron and Bayer’s Eylea in retinal vein occlusion (RVO) shows that more patients on Vabysmo had an absence of blood vessel leakage in ...
Researchers also suggest potential new genetic associations with macular edema, which warrant further research. A study published in Scientific Reports confirmed previously identified retinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback